The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms

Journal of Molecular Medicine

Volumn 90, Issue 6, 2012, Pages 667-679

  Ciuffreda, Ludovica ^a   Di Sanza, Cristina ^a   Cesta Incani, Ursula ^a   Eramo, Adriana ^b   Desideri, Marianna ^a   Biagioni, Francesca ^a   Passeri, Daniela ^c   Falcone, Italia ^a   Sette, Giovanni ^b   Bergamo, Paola ^a   Anichini, Andrea ^d   Sabapathy, Kanaga ^e   McCubrey, James A ^f   Ricciardi, Maria Rosaria ^g   Tafuri, Agostino ^g   Blandino, Giovanni ^a   Orlandi, Augusto ^c   De Maria, Ruggero ^b   Cognetti, Francesco ^a   Del Bufalo, Donatella ^a   Milella, Michele ^a   more..

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^f EAST CAROLINA UNIVERSITY   (United States)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

c Jun; Crosstalk; MAPK; miR 25; PI3K; PTEN

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN C JUN; TEMSIROLIMUS; TRAMETINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BENZAMIDES; DIPHENYLAMINE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MELANOMA; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 84862649725     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-011-0844-1     Document Type: Article

References (37)

1. GS Martin 2003 Cell signaling and cancer Cancer Cell 4 167 174 14522250 10.1016/S1535-6108(03)00216-2 1:CAS:528:DC%2BD3sXotFKlsr0%3D
2. Milella M, Ciuffreda L, Bria E (2009) Signal transduction pathways as therapeutic targets in cancer therapy. 37: 83
3. DA Guertin DM Sabatini 2007 Defining the role of mTOR in cancer Cancer Cell 12 9 22 17613433 10.1016/j.ccr.2007.05.008 1:CAS:528:DC%2BD2sXotVyqsr0%3D
4. L Ciuffreda JA McCubrey M Milella 2009 Signaling intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK pathways) as therapeutic targets for anti-cancer and anti angiogenesis treatments Curr Signal Transduct Ther 4 130 143 10.2174/157436209788167466 1:CAS:528:DC%2BD1MXlslOlsLs%3D
5. JA Engelman L Chen X Tan K Crosby AR Guimaraes R Upadhyay M Maira K McNamara SA Perera Y Song, et al. 2008 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 1351 1356 19029981 10.1038/nm.1890 1:CAS:528:DC%2BD1cXhsVWhu7rI
6. CW Kinkade M Castillo-Martin A Puzio-Kuter J Yan TH Foster H Gao Y Sun X Ouyang WL Gerald C Cordon-Cardo, et al. 2008 Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model J Clin Invest 118 3051 3064 18725989 1:CAS:528:DC%2BD1cXhtV2isb3N
7. H Davies GR Bignell C Cox P Stephens S Edkins S Clegg J Teague H Woffendin MJ Garnett W Bottomley, et al. 2002 Mutations of the BRAF gene in human cancer Nature 417 949 954 12068308 10.1038/nature00766 1:CAS:528:DC%2BD38XkvVagsLo%3D
8. DB Solit LA Garraway CA Pratilas A Sawai G Getz A Basso Q Ye JM Lobo Y She I Osman, et al. 2006 BRAF mutation predicts sensitivity to MEK inhibition Nature 439 358 362 16273091 10.1038/nature04304 1:CAS:528:DC%2BD28XkvF2mtw%3D%3D
9. L Ciuffreda BD Del M Desideri SC Di A Stoppacciaro MR Ricciardi S Chiaretti S Tavolaro B Benassi A Bellacosa, et al. 2009 Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations Neoplasia 11 720 731 19649202 1:CAS:528:DC%2BD1MXoslKitbY%3D
10. GP Robertson RA Herbst M Nagane HJ Huang WK Cavenee 1999 The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci Cancer Res 59 3596 3601 10446968 1:CAS:528:DyaK1MXltFCguro%3D
11. V600E cooperates with Pten loss to induce metastatic melanoma Nat Genet 41 544 552 19282848 10.1038/ng.356 1:CAS:528:DC%2BD1MXjtFCisbY%3D
12. A Eramo F Lotti G Sette E Pilozzi M Biffoni VA Di C Conticello L Ruco C Peschle MR De 2008 Identification and expansion of the tumorigenic lung cancer stem cell population Cell Death Differ 15 504 514 18049477 10.1038/sj.cdd. 4402283 1:CAS:528:DC%2BD1cXitVOlsLo%3D
13. M Milella D Trisciuoglio T Bruno L Ciuffreda M Mottolese A Cianciulli F Cognetti U Zangemeister-Wittke D Del Bufalo G Zupi 2004 Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells Clin Cancer Res 10 7747 7756 15570009 10.1158/1078-0432.CCR- 04-0908 1:CAS:528:DC%2BD2cXhtVanur3F
14. K Hettinger F Vikhanskaya MK Poh MK Lee I de Belle JT Zhang SA Reddy K Sabapathy 2007 c-Jun promotes cellular survival by suppression of PTEN Cell Death Differ 14 218 229 16676006 10.1038/sj.cdd.4401946 1:CAS:528: DC%2BD2sXkslCisw%3D%3D
15. A von Gise P Lorenz C Wellbrock B Hemmings F Berberich-Siebelt UR Rapp J Troppmair 2001 Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals Mol Cell Biol 21 2324 2336 10.1128/MCB.21.7.2324-2336.2001
16. P Lopez-Bergami C Huang JS Goydos D Yip M Bar-Eli M Herlyn KS Smalley A Mahale A Eroshkin S Aaronson, et al. 2007 Rewired ERK-JNK signaling pathways in melanoma Cancer Cell 11 447 460 17482134 10.1016/j.ccr.2007.03.009 1:CAS:528:DC%2BD2sXlsVagsr8%3D
17. MJ Robinson SA Stippec E Goldsmith MA White MH Cobb 1998 A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation Curr Biol 8 1141 1150 9799732 10.1016/S0960-9822(07)00485-X 1:CAS:528:DyaK1cXntFWgsLY%3D
18. NR Leslie A Gray I Pass EA Orchiston CP Downes 2000 Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase Biochem J 346 Pt 3 827 833 10698713 10.1042/0264-6021:3460827 1:CAS:528:DC%2BD3cXit1KrsLo%3D
19. C Pisano CM De GL Beretta V Zuco G Pratesi S Penco L Vesci R Fodera FF Ferrara MB Guglielmi, et al. 2008 Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968 Mol Cancer Ther 7 2051 2059 18645015 10.1158/1535-7163.MCT-08-0266 1:CAS:528:DC%2BD1cXoslCgu78%3D
20. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 6382953 10.1016/0065-2571(84)90007-4 1:CAS:528: DyaL2cXktlaksLk%3D
21. KM Vasudevan R Burikhanov A Goswami VM Rangnekar 2007 Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras Cancer Res 67 10343 10350 17974977 10.1158/0008-5472.CAN-07-1827 1:CAS:528:DC%2BD2sXht1erurzE
22. L Poliseno L Salmena J Zhang B Carver WJ Haveman PP Pandolfi 2010 A coding-independent function of gene and pseudogene mRNAs regulates tumour biology Nature 465 1033 1038 20577206 10.1038/nature09144 1:CAS:528: DC%2BC3cXnvFSgtLk%3D
23. L Poliseno L Salmena L Riccardi A Fornari MS Song RM Hobbs P Sportoletti S Varmeh A Egia G Fedele, et al. 2010 Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation Sci Signal 3 ra29 20388916 10.1126/scisignal. 2000594
24. M Ming W Han J Maddox K Soltani CR Shea DM Freeman YY He 2010 UVB-induced ERK/AKT-dependent PTEN suppression promotes survival of epidermal keratinocytes Oncogene 29 492 502 19881543 10.1038/onc.2009.357 1:CAS:528:DC%2BD1MXhtlers7fL
25. W Wei J Jin S Schlisio JW Harper WG Kaelin Jr 2005 The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase Cancer Cell 8 25 33 16023596 10.1016/j.ccr.2005.06.005 1:CAS:528:DC%2BD2MXntVejs70%3D
26. J Bain L Plater M Elliott N Shpiro CJ Hastie H McLauchlan I Klevernic JS Arthur DR Alessi P Cohen 2007 The selectivity of protein kinase inhibitors: a further update Biochem J 408 297 315 17850214 10.1042/BJ20070797 1:CAS:528:DC%2BD2sXhtlGmtbjE
27. BH Jiang LZ Liu 2009 PI3K/PTEN signaling in angiogenesis and tumorigenesis Adv Cancer Res 102 19 65 19595306 10.1016/S0065-230X(09)02002-8 1:CAS:528:DC%2BD1MXht1ektLbM
28. B Kwabi-Addo D Giri K Schmidt K Podsypanina R Parsons N Greenberg M Ittmann 2001 Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression Proc Natl Acad Sci U S A 98 11563 11568 11553783 10.1073/pnas.201167798 1:CAS:528:DC%2BD3MXnt12jsrc%3D
29. NR Leslie CP Downes 2004 PTEN function: how normal cells control it and tumour cells lose it Biochem J 382 1 11 15193142 10.1042/BJ20040825 1:CAS:528:DC%2BD2cXmsVChsLo%3D
30. LC Trotman M Niki ZA Dotan JA Koutcher CA Di A Xiao AS Khoo P Roy-Burman NM Greenberg DT Van, et al. 2003 Pten dose dictates cancer progression in the prostate PLoS Biol 1 E59 14691534 10.1371/journal.pbio.0000059
31. M Ming YY He 2009 PTEN: new insights into its regulation and function in skin cancer J Invest Dermatol 129 2109 2112 19340009 10.1038/jid.2009.79 1:CAS:528:DC%2BD1MXhtF2qsL3J
32. H Tsao X Zhang E Benoit FG Haluska 1998 Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines Oncogene 16 3397 3402 9692547 10.1038/sj.onc.1201881 1:CAS:528:DyaK1cXks1ensLc%3D
33. JM Stahl A Sharma M Cheung M Zimmerman JQ Cheng MW Bosenberg M Kester L Sandirasegarane GP Robertson 2004 Deregulated Akt3 activity promotes development of malignant melanoma Cancer Res 64 7002 7010 15466193 10.1158/0008-5472.CAN- 04-1399 1:CAS:528:DC%2BD2cXotFalsLo%3D
34. WM Lin AC Baker R Beroukhim W Winckler W Feng JM Marmion E Laine H Greulich H Tseng C Gates, et al. 2008 Modeling genomic diversity and tumor dependency in malignant melanoma Cancer Res 68 664 673 18245465 10.1158/0008-5472.CAN-07-2615 1:CAS:528:DC%2BD1cXhtlygsrw%3D
35. H Tsao V Goel H Wu G Yang FG Haluska 2004 Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma J Invest Dermatol 122 337 341 15009714 10.1046/j.0022-202X.2004.22243.x 1:CAS:528:DC%2BD2cXitlGitbg%3D
36. S Wee Z Jagani KX Xiang A Loo M Dorsch YM Yao WR Sellers C Lengauer F Stegmeier 2009 PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers Cancer Res 69 4286 4293 19401449 10.1158/0008-5472.CAN-08- 4765 1:CAS:528:DC%2BD1MXlvFWltLg%3D
37. YN Gopal W Deng SE Woodman K Komurov P Ram PD Smith MA Davies 2010 Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells Cancer Res 70 8736 8747 20959481 10.1158/0008-5472.CAN-10-0902 1:CAS:528: DC%2BC3cXhtlKjt7%2FJ